A possible explanation of this survival advantage for cancer cells was proposed by Chen et al., who showed that the binding between α4 integrins on MAMs and VCAM-1 on tumor cells can trigger the Ezrin-PI3K/Akt anti-apoptotic pathway in the latter [117]. The gene discussed is VCAM1; the disease is cancer.